1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sorrento, Under Shadow Of Chapter 11, Looks To Move BTK Inhibitor Into Phase III

 
• By Alaric DeArment

The biotech announced promising Phase IIa results for abivertinib in marginal zone lymphoma and is in talks with Chinese regulators about a Phase III trial.

Sorrento announced results from its Phase IIa trial of abivertinib in marginal zone lymphoma • Source: Shutterstock

Sorrento Therapeutics, Inc.’s BTK inhibitor, abivertinib, has potential to fill the vacuum in marginal zone lymphoma (MZL) that AbbVie Inc. and Johnson & Johnson left in April when they withdrew the indication for the BTK/EGFR inhibitor, Imbruvica (imbruvica), in that disease as well as mantle cell lymphoma (MCL) following lackluster Phase III confirmatory trial results. Sorrento could be in an especially strong position if it can continue to show a favorable safety profile.

Sorrento plans to move abivertinib into pivotal Phase III development in China following the announcement of successful Phase IIa results, though it is currently under Chapter 11 bankruptcy protection in the US, and based on prior experience with the drug in lung

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.